• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Jumps 400 Points; US Retail Sales Flat For June

    7/16/24 10:04:30 AM ET
    $AMIX
    $CMND
    $CYN
    $LPA
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMIX alert in real time by email

    U.S. stocks traded higher this morning, with the Dow Jones index rising more than 400 points on Tuesday.

    Following the market opening Tuesday, the Dow traded up 1% to 40,614.31 while the NASDAQ rose 0.14% to 18,498.00. The S&P 500 also rose, gaining, 0.33% to 5,649.84.

    Check This Out: Wall Street’s Most Accurate Analysts Weigh In On 3 Industrials Stocks Delivering High-Dividend Yields

    Leading and Lagging Sectors

    Industrials shares jumped by 1.2% on Tuesday.

    In trading on Tuesday, energy shares fell by 0.6%.

    Top Headline

    U.S. retail sales came in flat month-over-month for June compared to a revised 0.3% gain in the previous period.

    Equities Trading UP
                           

    • Silo Pharma, Inc. (NASDAQ:SILO) shares shot up 83% to $1.97 after the company obtained an exclusive global license to develop, manufacture, and commercialize its Alzheimer’s drug.
    • Shares of Yoshitsu Co., Ltd (NASDAQ:TKLF) got a boost, surging 78% to $0.5450 after the company reported a year-over-year increase in FY24 financial results.
    • Logistic Properties of the Americas (NYSE:LPA) shares were also up, gaining 37% to $21.06.

    Equities Trading DOWN

    • Autonomix Medical, Inc. (NASDAQ:AMIX) shares dropped 22% to $1.08. Autonomix shares jumped 130% on Monday after the company entered into an agreement with RF Innovations to license intellectual property for its Apex 6 Radiofrequency Generator.
    • Shares of Cyngn Inc. (NASDAQ:CYN) were down 21% to $7.28 after jumping 54% on Monday.
    • Clearmind Medicine Inc (NASDAQ:CMND) was down, falling 14% to $1.8950. Clearmind Medicine announced the FDA clearance for IND application of MEAI-based CMND-100 oral capsule.

    Also Check This Out: Tecogen And 3 Other Stocks Under $5 Insiders Are Buying

    Commodities

    In commodity news, oil traded down 1.6% to $80.61 while gold traded up 0.7% at $2,445.10.

    Silver traded up 0.5% to $31.095 on Tuesday, while copper fell 0.6% to $4.5005.

    Euro zone

    European shares were lower today. The eurozone's STOXX 600 fell 0.5, Germany's DAX fell 0.6% and France's CAC 40 fell 0.8%. Spain's IBEX 35 Index fell 0.9%, while London's FTSE 100 fell 0.4%.

    The ZEW Indicator of Economic Sentiment for the Eurozone fell by 7.6 points to a reading of 43.7 in July, while Eurozone posted a trade surplus of EUR 13.9 billion in May versus a year-ago gap of EUR 0.4 billion.

    The ZEW Indicator of Economic Sentiment for Germany fell to 41.8 in July, recording the first decline in a year. Italy reported a trade surplus of EUR 6.43 billion in May versus a year-ago surplus of EUR 4.767 billion year.

    Asia Pacific Markets

    Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 gaining 0.20%, Hong Kong's Hang Seng Index falling 1.60%, China's Shanghai Composite Index gaining 0.08% and India's S&P BSE Sensex gaining 0.06%.

    Economics

    • U.S. retail sales came in flat month-over-month for June compared to a revised 0.3% gain in the previous period.
    • Import prices came in unchanged from the prior month in June, while export prices in the U.S. declined 0.5% month-over-month in June.

    Now Read This:

    • Top 5 Financials Stocks That May Collapse This Month
    Get the next $AMIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMIX
    $CMND
    $CYN
    $LPA

    CompanyDatePrice TargetRatingAnalyst
    Cyngn Inc.
    $CYN
    11/16/2021$13.00Buy
    Aegis Capital
    More analyst ratings

    $AMIX
    $CMND
    $CYN
    $LPA
    SEC Filings

    View All

    SEC Form 10-Q filed by Autonomix Medical Inc.

    10-Q - Autonomix Medical, Inc. (0001617867) (Filer)

    2/11/26 5:00:59 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Clearmind Medicine Inc.

    6-K - Clearmind Medicine Inc. (0001892500) (Filer)

    2/11/26 4:15:31 PM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyngn Inc. filed SEC Form 8-K: Leadership Update

    8-K - Cyngn Inc. (0001874097) (Filer)

    2/9/26 4:31:01 PM ET
    $CYN
    EDP Services
    Technology

    $AMIX
    $CMND
    $CYN
    $LPA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aegis Capital initiated coverage on Cyngn with a new price target

    Aegis Capital initiated coverage of Cyngn with a rating of Buy and set a new price target of $13.00

    11/16/21 9:25:59 AM ET
    $CYN
    EDP Services
    Technology

    $AMIX
    $CMND
    $CYN
    $LPA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Weisblum Eric bought $2,075 worth of shares (5,000 units at $0.41), increasing direct ownership by 2% to 216,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    12/16/25 6:34:59 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Executive Officer Weisblum Eric bought $735 worth of shares (2,000 units at $0.37), increasing direct ownership by 0.95% to 211,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/21/25 6:35:50 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Executive Officer Weisblum Eric bought $4,847 worth of shares (12,000 units at $0.40), increasing direct ownership by 6% to 209,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/20/25 4:00:32 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $AMIX
    $CMND
    $CYN
    $LPA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Weisblum Eric bought $2,075 worth of shares (5,000 units at $0.41), increasing direct ownership by 2% to 216,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    12/16/25 6:34:59 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Executive Officer Weisblum Eric bought $735 worth of shares (2,000 units at $0.37), increasing direct ownership by 0.95% to 211,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/21/25 6:35:50 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    Chief Executive Officer Weisblum Eric bought $4,847 worth of shares (12,000 units at $0.40), increasing direct ownership by 6% to 209,932 units (SEC Form 4)

    4 - Silo Pharma, Inc. (0001514183) (Issuer)

    11/20/25 4:00:32 PM ET
    $SILO
    Apparel
    Consumer Discretionary

    $AMIX
    $CMND
    $CYN
    $LPA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

    Vancouver, Canada, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced additional positive safety topline results from the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company's proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). These further safety data points, emerging following the successful completion of treatment in another six pati

    2/9/26 8:17:00 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

    Collaboration aims to leverage Polyrizon's advanced proprietary intranasal delivery platform to support clinical development of Clearmind's drug candidate proprietary MEAI Raanana, Israel, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has entered into a development agreement with Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind"), a clinical‑stage biopharmaceutical company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems. Under this agreement, Polyr

    2/6/26 7:55:00 AM ET
    $CMND
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI

    Collaboration aims to enhance bioavailability and support clinical advancement of Clearmind's lead MEAI candidate for addiction-related and other CNS disorders Vancouver, Canada, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it has entered into a development agreement with Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon"), a pre-clinical-stage biotechnology company developing advanced intranasal delivery solutions. Under the agreement, Clear

    2/6/26 7:55:00 AM ET
    $CMND
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMIX
    $CMND
    $CYN
    $LPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    12/3/24 6:17:58 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    11/27/24 10:15:18 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Clearmind Medicine Inc.

    SC 13G/A - Clearmind Medicine Inc. (0001892500) (Subject)

    11/14/24 5:08:52 PM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMIX
    $CMND
    $CYN
    $LPA
    Financials

    Live finance-specific insights

    View All

    Tokyo Lifestyle Co., Ltd. Announces Payment of Interim Dividend for Fiscal Year 2026

    Tokyo, Japan, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Tokyo Lifestyle Co., Ltd. ("Tokyo Lifestyle" or the "Company") (NASDAQ:TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, collectible cards, trendy toys as well as other products in Hong Kong, Japan, North America, Thailand, Vietnam, the United Kingdom and Australia, today announced that the interim dividend of JPY1.890 per share for the fiscal year ending March 31, 2026 previously approved by its board of directors was paid on December 19, 2025 (Japan Standard Time) to shareholders of record as of September 30, 2025 (Japan Standard Time), with an American depositary

    12/22/25 8:00:00 AM ET
    $TKLF
    Other Specialty Stores
    Consumer Discretionary

    Tokyo Lifestyle Co., Ltd. Reports First Six Months of Fiscal Year 2026 Financial Results

    Revenue Increased by 94.3% YoY; Gross Profit Increased by 29.8% YoY TOKYO, Dec. 19, 2025 /PRNewswire/ -- Tokyo Lifestyle Co., Ltd. ("Tokyo Lifestyle" or the "Company") (NASDAQ:TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, collectible cards, trendy toys as well as other products in Hong Kong, Japan, North America, Thailand, Vietnam, the United Kingdom and Australia, today announced its unaudited financial results for the first six months of the fiscal year 2026 ended September 30, 2025. Mr. Mei Kanayama, Principal Executive Officer of Tokyo Lifestyle, commented: "The first half of fiscal year 2026 delivered bro

    12/19/25 4:05:00 PM ET
    $TKLF
    Other Specialty Stores
    Consumer Discretionary

    Cyngn Reports Third Quarter 2025 Financial Results

    Recent Operating Highlights Deployed the DriveMod Tugger at G&J Pepsi, the Largest Independent Pepsi Bottler in the USAU.S. Continental "definitely recommends" the DriveMod Tugger.Secured funding that extends Cyngn's cash runway through 2027, reinforcing balance-sheet stability and capacity to scale operations.Appointed Natalie Russell as Chief Financial Officer to strengthen financial leadership and operational discipline.Expanded the sales organization to the largest in company history, reflecting a more mature commercial posture.Deployed the DriveMod Tugger at Coats, marking another live industrial implementation of Cyngn's autonomous vehicle technology.Secured Cyngn's 23rd U.S. patent, c

    11/18/25 5:41:00 PM ET
    $CYN
    EDP Services
    Technology

    $AMIX
    $CMND
    $CYN
    $LPA
    Leadership Updates

    Live Leadership Updates

    View All

    Cyngn Partners with Chandler Automation, Expands into Agriculture

    MOUNTAIN VIEW, Calif., Dec. 23, 2025 /PRNewswire/ -- Cyngn (NASDAQ:CYN) today announced that Chandler Automation has joined its dealer network and will begin offering Cyngn's autonomous DriveMod Tugger to food processors and packers in the agriculture sector. Chandler Automation is a full-service partner in factory automation, specializing in optical sorting, inspection, robotic palletizing, and custom processing machinery. Known for delivering tailored, high-performance systems, Chandler empowers food processors to reduce labor costs, boost efficiency, and stay competitive wi

    12/23/25 7:00:00 AM ET
    $CYN
    EDP Services
    Technology

    Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

    Vancouver, Canada, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received final approval from the Hadassah Medical Center, Jerusalem, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable Hadassah Medical Center, a leading clinical site in Israel, to join the Company's clinical trial, of which the fir

    11/13/25 8:54:39 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement

    Vancouver, Canada, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogens-derived therapeutics to solve major under-treated health problems, today announced the appointment of Mary-Elizabeth Gifford as Chief of Global Impact. In this role, Gifford will lead efforts to strengthen Clearmind's US partnerships, governmental and regulatory advocacy, and strategic alliances in Washington, D.C. and New York, bridging research, regulation, and patient care to accelerate the advancement of innovative psychedelic medicines. Prior to joining Cl

    10/27/25 9:22:00 AM ET
    $CMND
    Biotechnology: Pharmaceutical Preparations
    Health Care